Yepes M - Search Results

1

Association between conformational mutations in neuroserpin and onset and severity of dementia.

Davis RL, Shrimpton AE, Carrell RW, Lomas DA, Gerhard L, Baumann B, Lawrence DA, Yepes M, Kim TS, Ghetti B, Piccardo P, Takao M, Lacbawan F, Muenke M, Sifers RN, Bradshaw CB, Kent PF, Collins GH, Larocca D, Holohan PD. Davis RL, et al. Among authors: yepes m. Lancet. 2002 Jun 29;359(9325):2242-7. doi: 10.1016/S0140-6736(02)09293-0. Lancet. 2002. PMID: 12103288

2

Neuroserpin: a selective inhibitor of tissue-type plasminogen activator in the central nervous system.

Yepes M, Lawrence DA. Yepes M, et al. Thromb Haemost. 2004 Mar;91(3):457-64. doi: 10.1160/TH03-12-0766. Thromb Haemost. 2004. PMID: 14983220 Review.

3

Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system?

Yepes M, Lawrence DA. Yepes M, et al. Trends Cardiovasc Med. 2004 Jul;14(5):173-80. doi: 10.1016/j.tcm.2004.03.004. Trends Cardiovasc Med. 2004. PMID: 15261888 Review.

4

New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system.

Yepes M, Lawrence DA. Yepes M, et al. Exp Biol Med (Maywood). 2004 Dec;229(11):1097-104. doi: 10.1177/153537020422901103. Exp Biol Med (Maywood). 2004. PMID: 15564435 Review.

5

Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent.

Yepes M, Sandkvist M, Coleman TA, Moore E, Wu JY, Mitola D, Bugge TH, Lawrence DA. Yepes M, et al. J Clin Invest. 2002 Jun;109(12):1571-8. doi: 10.1172/JCI14308. J Clin Invest. 2002. PMID: 12070304 Free PMC article.

6

Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.

Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P, Coleman TA, Lawrence DA, Chopp M. Zhang Z, et al. Among authors: yepes m. Circulation. 2002 Aug 6;106(6):740-5. doi: 10.1161/01.cir.0000023942.10849.41. Circulation. 2002. PMID: 12163437

7

Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis.

Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL, Lawrence DA. Yepes M, et al. Blood. 2000 Jul 15;96(2):569-76. Blood. 2000. PMID: 10887120 Free article.

8

Neuroserpin polymorphisms and stroke risk in a biracial population: the stroke prevention in young women study.

Cole JW, Naj AC, O'Connell JR, Stine OC, Sorkin JD, Wozniak MA, Stern BJ, Yepes M, Lawrence DA, Reinhart LJ, Strickland DK, Mitchell BD, Kittner SJ. Cole JW, et al. Among authors: yepes m. BMC Neurol. 2007 Oct 25;7:37. doi: 10.1186/1471-2377-7-37. BMC Neurol. 2007. PMID: 17961231 Free PMC article.

9

Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.

Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Yepes M, et al. J Clin Invest. 2003 Nov;112(10):1533-40. doi: 10.1172/JCI19212. J Clin Invest. 2003. PMID: 14617754 Free PMC article.

10

A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia.

Yepes M, Brown SA, Moore EG, Smith EP, Lawrence DA, Winkles JA. Yepes M, et al. Am J Pathol. 2005 Feb;166(2):511-20. doi: 10.1016/S0002-9440(10)62273-0. Am J Pathol. 2005. PMID: 15681834 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

196 results

Search Page